Celgene Stock Fundamentals
Celgene fundamentals help investors to digest information that contributes to Celgene's financial success or failures. It also enables traders to predict the movement of Celgene Stock. The fundamental analysis module provides a way to measure Celgene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celgene stock.
Celgene |
Celgene Company Operating Margin Analysis
Celgene's Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Celgene Operating Margin | 51.47 % |
Most of Celgene's fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celgene is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
CompetitionBased on the recorded statements, Celgene has an Operating Margin of 51%. This is 246.72% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The operating margin for all United States stocks is notably lower than that of the firm.
Celgene Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Celgene's current stock value. Our valuation model uses many indicators to compare Celgene value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Celgene competition to find correlations between indicators driving Celgene's intrinsic value. More Info.Celgene is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 1,400 of Return On Asset per Return On Equity. Comparative valuation analysis is a catch-all technique that is used if you cannot value Celgene by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Celgene Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celgene's direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celgene could also be used in its relative valuation, which is a method of valuing Celgene by comparing valuation metrics of similar companies.Celgene is currently under evaluation in operating margin category among its peers.
Celgene Fundamentals
| Return On Equity | 1.0E-4 | |||
| Return On Asset | 0.14 | |||
| Profit Margin | 0.30 % | |||
| Operating Margin | 51.47 % | |||
| Current Valuation | 85.34 B | |||
| Shares Outstanding | 708.74 M | |||
| Shares Owned By Insiders | 0.22 % | |||
| Shares Owned By Institutions | 77.62 % | |||
| Number Of Shares Shorted | 12.95 M | |||
| Price To Earning | 13.31 X | |||
| Price To Book | 7.45 X | |||
| Price To Sales | 4.54 X | |||
| Revenue | 16.35 B | |||
| Gross Profit | 14.06 B | |||
| EBITDA | 8.42 B | |||
| Net Income | 5.27 B | |||
| Cash And Equivalents | 9.32 B | |||
| Cash Per Share | 13.15 X | |||
| Total Debt | 20.1 B | |||
| Debt To Equity | 199.90 % | |||
| Current Ratio | 3.44 X | |||
| Book Value Per Share | 9.22 X | |||
| Cash Flow From Operations | 6.35 B | |||
| Short Ratio | 3.45 X | |||
| Earnings Per Share | 7.32 X | |||
| Price To Earnings To Growth | 0.67 X | |||
| Number Of Employees | 8.85 K | |||
| Beta | 1.41 | |||
| Market Capitalization | 77.04 B | |||
| Total Asset | 1.11 B | |||
| Retained Earnings | 21.79 B | |||
| Working Capital | 708.47 M | |||
| Current Asset | 849.88 M | |||
| Current Liabilities | 141.41 M | |||
| Z Score | 69.79 |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Celgene Stock
If you are still planning to invest in Celgene check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Celgene's history and understand the potential risks before investing.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |